share_log

Amgen | 10-Q: Q2 2024 Earnings Report

Amgen | 10-Q: Q2 2024 Earnings Report

安進 | 10-Q：2024財年二季報
美股SEC公告 ·  2024/08/08 04:05

Moomoo AI 已提取核心訊息

Amgen reported Q2 2024 total revenues of $8.4 billion, up 20% year-over-year, driven by 26% volume growth partially offset by a 3% decline in net selling price. Product sales increased to $8.0 billion, with U.S. sales up 23% to $5.8 billion and ROW sales up 13% to $2.2 billion. Acquired Horizon products contributed $1.1 billion in sales.Operating expenses rose 51% to $6.5 billion, primarily due to higher amortization from Horizon acquisition-related assets. Operating income decreased 29% to $1.9 billion, while net income fell 46% to $746 million. The effective tax rate decreased to 6.0% from 14.6% in Q2 2023, mainly due to earnings mix from the Horizon business inclusion.Strong performance was seen across key products, with Repatha sales up 25% to $532 million, TEZSPIRE up 76% to $234 million, and EVENITY up 39% to $391 million. However, ENBREL sales declined 15% to $909 million due to lower net selling price. The company maintains focus on debt reduction and returning capital to shareholders through dividends.
Amgen reported Q2 2024 total revenues of $8.4 billion, up 20% year-over-year, driven by 26% volume growth partially offset by a 3% decline in net selling price. Product sales increased to $8.0 billion, with U.S. sales up 23% to $5.8 billion and ROW sales up 13% to $2.2 billion. Acquired Horizon products contributed $1.1 billion in sales.Operating expenses rose 51% to $6.5 billion, primarily due to higher amortization from Horizon acquisition-related assets. Operating income decreased 29% to $1.9 billion, while net income fell 46% to $746 million. The effective tax rate decreased to 6.0% from 14.6% in Q2 2023, mainly due to earnings mix from the Horizon business inclusion.Strong performance was seen across key products, with Repatha sales up 25% to $532 million, TEZSPIRE up 76% to $234 million, and EVENITY up 39% to $391 million. However, ENBREL sales declined 15% to $909 million due to lower net selling price. The company maintains focus on debt reduction and returning capital to shareholders through dividends.
安進報告2024年第二季度總收入達84億元，同比增長20%，主要由於成交量增長26%，部分被淨售價下降3%所抵消。產品銷售額增加至80億元，美國銷售額增長23%至58億元，其他地區銷售額增長13%至22億元。收購的Horizon產品貢獻了11億元的銷售額。營業費用增長51%至65億元，主要由於與Horizon收購相關資產的攤銷增加。營業收入下降29%至19億元，而凈利潤下降46%至74600萬元。有效稅率從2023年第二季度的14.6%降至6.0%，主要由於Horizon業務納入後的收益組合。關鍵產品表現強勁，Repatha銷售增長25%至53200萬元，TEZSPIRE增長76%至23400萬元，而EVENITY增長39%至39100萬元。然而，ENBREL銷售下降15%至90900萬元，主要由於淨售價下降。公司專注於減少債務並通過分紅派息將資本返還給股東。
安進報告2024年第二季度總收入達84億元，同比增長20%，主要由於成交量增長26%，部分被淨售價下降3%所抵消。產品銷售額增加至80億元，美國銷售額增長23%至58億元，其他地區銷售額增長13%至22億元。收購的Horizon產品貢獻了11億元的銷售額。營業費用增長51%至65億元，主要由於與Horizon收購相關資產的攤銷增加。營業收入下降29%至19億元，而凈利潤下降46%至74600萬元。有效稅率從2023年第二季度的14.6%降至6.0%，主要由於Horizon業務納入後的收益組合。關鍵產品表現強勁，Repatha銷售增長25%至53200萬元，TEZSPIRE增長76%至23400萬元，而EVENITY增長39%至39100萬元。然而，ENBREL銷售下降15%至90900萬元，主要由於淨售價下降。公司專注於減少債務並通過分紅派息將資本返還給股東。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

獨立文件7  查看翻譯

獨立文件8  查看翻譯

獨立文件9  查看翻譯

獨立文件10  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    禮來
    LLY
    -- 799.900
    吉利德科學
    GILD
    -- 89.880
    諾和諾德
    NVO
    -- 86.260
    阿斯利康
    AZN
    -- 67.010
    Scilex Holding
    SCLX
    -- 0.455

    解鎖榜首股票

    熱門討論
    特朗普2.0時代倒計時！全球股市的下一個風口？
    特朗普即將重返政治舞台！他提出的“美國優先”關稅政策、加密貨幣政策以及對科技行業的影響，已成為市場關注的焦點。在此背景下，加密貨幣、特斯拉、AI板塊的未來走勢值得關注。 🎙️️討論： 1. 加密貨幣政策能否利好crypto? 2. 關稅政策能否利好中概等海外資產？ 展开
    賣盤分析師 - 川普的第一天
    查看更多